SCHEMBL3945239

SCHEMBL3945239

Cc1cc(-c2c(C)cccc2C)nc(N)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 10/20 0.61
HSP90AB1 P08238 6/20 0.49
NUDT1 P36639 1/20 0.45
AURKA O14965 1/20 0.44
PDPK1 O15530 1/20 0.44
TGFBR1 P36897 1/20 0.44
ROCK1 Q13464 1/20 0.44
AURKB Q96GD4 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.42
GRM4 Q14833 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PIK3CD O00329 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CG P48736 1/20 0.42
SRC P12931 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14359627 0.88 HSP90AA1 (0.75) HSP90AA1HSP90AB1NUDT1AURKAPDPK1
SCHEMBL3946470 0.83 HSP90AA1 (0.56) HSP90AA1HSP90AB1AURKAPDPK1TGFBR1
SCHEMBL3950787 0.83 HSP90AA1 (0.79) HSP90AA1HSP90AB1NUDT1AURKAPDPK1
SCHEMBL20619965 0.82 NUDT1 (0.68) HSP90AA1HSP90AB1NUDT1AURKAPDPK1
SCHEMBL24331435 0.81 HSP90AA1 (0.50) HSP90AA1HSP90AB1NUDT1CYP1A2CYP2C9
SCHEMBL22501986 0.81 HSP90AA1 (0.66) HSP90AA1HSP90AB1KDM4E
SCHEMBL3952648 0.80 HSP90AA1 (0.81) HSP90AA1HSP90AB1KDM4E
Hydrochloric Acid SCHEMBL22502036 0.79 HSP90AA1 (0.64) HSP90AA1HSP90AB1KDM4E
SCHEMBL5748648 0.79 HSP90AA1 (0.49) HSP90AA1HSP90AB1NUDT1AURKAPDPK1
SCHEMBL24309274 0.78 HSP90AA1 (0.41) HSP90AA1HSP90AB1NUDT1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020206080-A1 CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-10-08 WO disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
EP-2049497-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS Astex Therapeutics Limited (GB) 2009-04-22 EP disclosed
WO-2006123165-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors HSP90AB1, HSP90AB2P, HSP90B1 HSP90AA1 4/4885HSP90AB1 1/4885NUDT1 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.